 Jonathan Shortt
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schistosoma japonicum | 2 | 2021 | 31 | 1.210 |
Why?
| | Schistosomiasis japonica | 2 | 2021 | 32 | 0.810 |
Why?
| | Genetic Variation | 4 | 2024 | 991 | 0.710 |
Why?
| | Microsatellite Repeats | 2 | 2018 | 168 | 0.630 |
Why?
| | Selection, Genetic | 2 | 2021 | 273 | 0.630 |
Why?
| | Metagenomics | 1 | 2021 | 169 | 0.630 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 539 | 0.400 |
Why?
| | Receptors, KIR | 3 | 2022 | 98 | 0.360 |
Why?
| | Pre-Eclampsia | 2 | 2023 | 190 | 0.350 |
Why?
| | China | 3 | 2021 | 217 | 0.340 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2025 | 2189 | 0.290 |
Why?
| | Placenta | 2 | 2023 | 750 | 0.260 |
Why?
| | Precision Medicine | 3 | 2024 | 429 | 0.230 |
Why?
| | Prealbumin | 1 | 2024 | 30 | 0.230 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2024 | 16 | 0.230 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2025 | 128 | 0.220 |
Why?
| | Pharmacogenetics | 2 | 2025 | 180 | 0.210 |
Why?
| | Thyroid Nodule | 1 | 2024 | 56 | 0.200 |
Why?
| | Genotype | 3 | 2024 | 1916 | 0.190 |
Why?
| | Receptors, KIR3DS1 | 1 | 2022 | 6 | 0.190 |
Why?
| | Receptors, KIR3DL1 | 1 | 2022 | 18 | 0.190 |
Why?
| | Jews | 1 | 2021 | 23 | 0.180 |
Why?
| | Collagen Type VII | 1 | 2021 | 28 | 0.180 |
Why?
| | Genes, MHC Class I | 1 | 2021 | 35 | 0.180 |
Why?
| | Epidermolysis Bullosa Dystrophica | 1 | 2021 | 41 | 0.180 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.170 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 85 | 0.170 |
Why?
| | Killer Cells, Natural | 2 | 2021 | 449 | 0.170 |
Why?
| | Evolution, Molecular | 2 | 2021 | 493 | 0.160 |
Why?
| | Thyroid Neoplasms | 1 | 2024 | 343 | 0.160 |
Why?
| | Software | 1 | 2024 | 665 | 0.150 |
Why?
| | Snakes | 1 | 2018 | 21 | 0.150 |
Why?
| | Lizards | 1 | 2018 | 35 | 0.140 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 102 | 0.140 |
Why?
| | Heterozygote | 1 | 2019 | 293 | 0.140 |
Why?
| | Primates | 1 | 2019 | 126 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 806 | 0.130 |
Why?
| | Genotyping Techniques | 1 | 2017 | 75 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2023 | 951 | 0.120 |
Why?
| | Genetics, Population | 1 | 2017 | 214 | 0.120 |
Why?
| | Genome | 1 | 2017 | 300 | 0.110 |
Why?
| | Phylogeny | 1 | 2018 | 904 | 0.110 |
Why?
| | Phenotype | 4 | 2024 | 3196 | 0.110 |
Why?
| | Humans | 17 | 2025 | 137585 | 0.110 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 812 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 2129 | 0.100 |
Why?
| | Colorado | 4 | 2024 | 4565 | 0.100 |
Why?
| | Genomics | 3 | 2024 | 795 | 0.100 |
Why?
| | HLA-B Antigens | 2 | 2022 | 62 | 0.090 |
Why?
| | Pilot Projects | 1 | 2017 | 1710 | 0.090 |
Why?
| | Neoplasms | 1 | 2025 | 2671 | 0.080 |
Why?
| | Animals | 4 | 2021 | 36940 | 0.080 |
Why?
| | Female | 9 | 2025 | 73304 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2111 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2531 | 0.070 |
Why?
| | Aged | 5 | 2025 | 23961 | 0.060 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1431 | 0.060 |
Why?
| | Vinca Alkaloids | 1 | 2025 | 6 | 0.060 |
Why?
| | Bridged-Ring Compounds | 1 | 2025 | 14 | 0.060 |
Why?
| | Male | 6 | 2025 | 67762 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5079 | 0.060 |
Why?
| | Taxoids | 1 | 2025 | 102 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2025 | 2426 | 0.060 |
Why?
| | Iran | 1 | 2023 | 43 | 0.050 |
Why?
| | Los Angeles | 1 | 2023 | 76 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 133 | 0.050 |
Why?
| | Cesarean Section | 1 | 2023 | 184 | 0.050 |
Why?
| | Chile | 1 | 2021 | 24 | 0.050 |
Why?
| | Colombia | 1 | 2021 | 41 | 0.050 |
Why?
| | Genetic Testing | 1 | 2024 | 460 | 0.050 |
Why?
| | Mississippi | 1 | 2021 | 21 | 0.040 |
Why?
| | Genes, Recessive | 1 | 2021 | 78 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 2021 | 55 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2021 | 35 | 0.040 |
Why?
| | Uterine Hemorrhage | 1 | 2021 | 37 | 0.040 |
Why?
| | Mexico | 1 | 2021 | 225 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 545 | 0.040 |
Why?
| | Drug Implants | 1 | 2021 | 82 | 0.040 |
Why?
| | Pregnancy | 2 | 2023 | 6763 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5472 | 0.040 |
Why?
| | Adult | 4 | 2025 | 37929 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 759 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1946 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 891 | 0.040 |
Why?
| | Oxygen | 1 | 2023 | 931 | 0.040 |
Why?
| | Altitude | 1 | 2023 | 488 | 0.040 |
Why?
| | Genome Size | 1 | 2018 | 11 | 0.040 |
Why?
| | Phylogeography | 1 | 2019 | 54 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1502 | 0.040 |
Why?
| | Hominidae | 1 | 2019 | 85 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2019 | 150 | 0.040 |
Why?
| | Fetal Growth Retardation | 1 | 2023 | 565 | 0.040 |
Why?
| | Middle Aged | 3 | 2025 | 33479 | 0.030 |
Why?
| | Prevalence | 1 | 2024 | 2734 | 0.030 |
Why?
| | Birds | 1 | 2018 | 93 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 570 | 0.030 |
Why?
| | DNA Transposable Elements | 1 | 2018 | 121 | 0.030 |
Why?
| | Weight Gain | 1 | 2021 | 519 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1079 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2025 | 1069 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 956 | 0.030 |
Why?
| | Self Report | 1 | 2021 | 827 | 0.030 |
Why?
| | Mammals | 1 | 2018 | 283 | 0.030 |
Why?
| | Hypoxia | 1 | 2023 | 1112 | 0.030 |
Why?
| | Protein Conformation | 1 | 2019 | 934 | 0.030 |
Why?
| | Indians, North American | 1 | 2021 | 643 | 0.030 |
Why?
| | Young Adult | 2 | 2022 | 13209 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2019 | 2139 | 0.030 |
Why?
| | Biological Evolution | 1 | 2019 | 474 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2804 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1570 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3295 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2024 | 7635 | 0.020 |
Why?
| | Protein Binding | 1 | 2019 | 2224 | 0.020 |
Why?
| | Prognosis | 1 | 2021 | 4030 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3457 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6828 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4149 | 0.020 |
Why?
| | Risk Factors | 1 | 2023 | 10388 | 0.020 |
Why?
| | United States | 1 | 2021 | 14841 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 21513 | 0.010 |
Why?
|
|
Shortt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|